BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/14/2025 5:49:36 AM | Browse: 292 | Download: 819
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 108535
Country China
ISSN 1948-5204 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Basic Study
Article Title Interleukin-22 promotes cancer stemness and chemotherapy resistance in colorectal cancer via epidermal growth factor receptor/extracellular signal-regulated kinase pathway
Manuscript Source Unsolicited Manuscript
All Author List Hong-Xun Ruan, Yan-Le Fang, Xiao-Ning Qin and Lin Lin
ORCID
Author(s) ORCID Number
Lin Lin http://orcid.org/0000-0001-9656-3526
Funding Agency and Grant Number
Corresponding Author Lin Lin, MD, The Third Department of General Surgery, The second Hospital of Hebei Medical University, No. 215 Heping West Road, Shijiazhuang 050004, Hebei Province, China. linlin779242000@163.com
Key Words Interleukin-22; Colorectal cancer; Oxaliplatin; Epidermal growth factor receptor; Extracellular signal-regulated kinase
Core Tip This study reveals that interleukin-22 (IL-22) enhances stem cell-like traits and promotes resistance to oxaliplatin in colorectal cancer (CRC) cells. Mechanistically, IL-22 activates the epidermal growth factor receptor (EGFR)/extracellular signal-regulated kinase signaling pathway. Inhibition of EGFR with osimertinib reverses IL-22-induced chemoresistance. These findings highlight IL-22 as a critical mediator of therapeutic resistance and a potential target for overcoming drug resistance in CRC treatment.
Publish Date 2025-08-14 05:49
Citation

Ruan HX, Fang YL, Qin XN, Lin L. Interleukin-22 promotes cancer stemness and chemotherapy resistance in colorectal cancer via epidermal growth factor receptor/extracellular signal-regulated kinase pathway. World J Gastrointest Oncol 2025; 17(8): 108535

URL https://www.wjgnet.com/1948-5204/full/v17/i8/108535.htm
DOI https://dx.doi.org/10.4251/wjgo.v17.i8.108535
Full Article (PDF) WJGO-17-108535-with-cover.pdf